Actemra IV (tocilizumab) / Roche, JW Pharma - LARVOL DELTA

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data (ASH 2025) - P | "Prior therapies included hematopoietic stem cell transplantation (HSCT) (24.1%), inotuzumab ozogamicin (14.8%), and blinatumomab (24.1%)...The median infusion dose was 0.60 (range: 0.44–1.00) × 10 8 viable CAR-T cells, with 88.9% of patients receiving bridge therapy...All patients recovered without sequelae: 9 received corticosteroids, and 11 received tocilizumab. Conclusion Real-world data demonstrate that Inati-cel exhibits excellent efficacy in patients with Ph+ B-ALL, yielding low toxicity, short treatment cycles, high complete molecular response rates, and favorable long-term survival. Extended follow-up could illuminate the long-term outcomes of Inati-cel use."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • ABL1 • IKZF1

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data (ASH 2025) - P | "Prior immunotherapies included: HSCT(21.4%), inotuzumab ozogamicin (18.6%), and blinatumomab (28.3%)...All patients recovered without sequelae, with 38 treatedwith corticosteroids, and 33 with tocilizumab or siltuximab.Real-world data on Inati-cel corroborates its robust response rate, favorable toxicity profile, and survivalbenefits. Real-world data on Inati-cel corroborates its robust response rate, favorable toxicity profile, and survivalbenefits. Inati-cel demonstrates efficacy in patients with active extramedullary diseases, particularlythose with CNSL. In vivo expansion was observed across different disease states."

Clinical • IO biomarker • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • CD4 • CD8 • IKZF1 • KMT2A • PAX5 • TP53

Deeper remission achievement and longer leukemia-free survival with inati-cel as consolidation therapy in allogeneic transplant-ineligible adolescent and adult patients with B-ALL (ASH 2025) - P1/2 | "All patients receivedlymphodepletion with fludarabine (30 mg/m2/d ×3 days) and cyclophosphamide (500 mg/m2/d×2 days) followed by Ina-cel infusion (0.6×108 live CAR-T cells)...Specially, only one patient had grade 3 CRS and grade 3 ICANS, characterized by high fever andhypotension, and was managed with tocilizumab in combination with dexamethasone (80 mg).Additionally, 7 patients (63.6%) suffered from cytopenia... Our preliminary results of the intervention study demonstrate inati-cel, a CD19 CAR-T celltherapy leads to high MRD-negativity conversion and survival rates with manageable toxicity intransplant-ineligible B-ALL patients. More patients are being enrolled and followed up. Long-termsurvival data are likely to support CD19 CAR-T cell therapy as a new paradigm for consolidation therapyfor B-ALL patients."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation

Real-world step-up dosing of patients receiving elranatamab for multiple myeloma in Japan (ASH 2025) - "Almost all patients received dexamethasone during the SUD period (Group A: 192 [99.5%], Group A+B: 217 [99.5%]) and acetaminophen (Group A: 191 [99.0%], Group A+B: 216 [99.1%]). Other supportive medications received include diphenhydramine (Group A: 109 [56.5%], Group A+B: 124 [56.9%]) and tocilizumab (Group A: 101 [52.3%], Group A+B: 120 [55.0%])...Both the frequency and timing of CRS and ICANS were generally consistent with past findings from elranatamab clinical trials. Despite the occurrence of CRS and ICANS events, many patients continued to receive complete and timely SUD."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Inflammation • Multiple Myeloma

Feasibility and safety of bispecific antibodies outpatient model in triple-refractory multiple myeloma patients in two Italian centers (ASH 2025) - "All patients underwent premedication with acetaminophen, chlorphenamine and dexamethasone during SUD and first full dose whereas three patients received post-medication with dexamethasone 16 mg the day after SUD1, SUD2 and first full dose...Seven patients were treated with teclistamab and one with talquetamab, approved after teclistamab in Italy...For both these two patients, tocilizumab was administered with rapid resolution of CRS and no need of hospitilization...A solid collaboration with emergency room doctors and nurses, the education of the patient and the outline of a path to rapidly and safely manage complications has been documented to be crucial. These encourage the feasibility of managing BSAbs therapy for MM patients in an outpatient setting in hub centres where multidisciplinary collaboration can be easily achieved."

Clinical • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience (ASH 2025) - "Twenty-two patients (73.3%) received R-CHOP as first-line chemoimmunotherapy...Two patients (6.7%) had prior anti-CD19 therapy, five (16.7%) had bendamustine exposure, and all patients received prior anti-CD20 monoclonal antibody...The most commonly used CART product was axicabtagene ciloleucel (N=28, 93%)...Tocilizumab was administered in 19 patients (63.3%), with 13 (68.4%) requiring only one dose...All ICANS patients received steroids, and four (33.3%) received anakinra...These findings affirm the safety and efficacy of autologous CD19-directed CAR T-cell therapy in routine clinical practice at a medium-sized academic institution. Continued research with larger sample sizes and extended follow-up periods is warranted to validate these results further."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Evaluation of payment reimbursement models for teclistamab administration and monitoring in the community hospital setting (ASH 2025) - "Five doses of tocilizumab were given in model 1 and 0 doses were given in model 2 (p=0.26). Eight doses of supplemental dexamethasone were given in model 1 and 7 doses were given in model 2 (p=0.88)...Conclusion Outpatient model 1 had significantly higher payment reimbursement and net profit margins compared to inpatient model 2. Our study showed that site of care is an important consideration with BsAbs to optimize revenue and minimize costs, in addition to enhancing access among community-based practices."

Clinical • Reimbursement • US reimbursement • Hematological Malignancies • Multiple Myeloma

Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis (ASH 2025) - "Like in the inpatient setting, patients developing CRS in the outpatient setting would be treated with 8mg/kg tocilizumab, steroids, or supportive care. While teclistamab SUD is currently predominantly administered in the inpatient setting in the Netherlands, there is consensus among clinical experts strongly indicating that teclistamab SUD can be administered feasibly, safely and conveniently in the outpatient setting. In addition, it leads to more efficient healthcare resource use and cost savings. While there is heterogeneity in prophylactic medication used to mitigate CRS, potential costs associated with this are largely offset by the hospitalisation costs and potential re-admission costs saved."

Clinical • HEOR • Hematological Malignancies • Multiple Myeloma

A rubric‑based comparison of code red and specialists in managing CAR‑T–Related cytokine release syndrome and icans (ASH 2025) - "Its margin was driven by a consistently protocol-level presentation—explicit monitoring schedules, predefined intervention thresholds (e.g., tocilizumab at 24 h of persistent fever), steroid regimens, ICU escalation criteria, and tertiary options (anakinra/siltuximab)—delivered in concise, highly actionable language. Conclusions A lean, expert-guided RAG system (Code Red) can outperform individual CAR-T specialists on simulated toxicity management scenarios while delivering rapid guidance. Ongoing improvement will rely on continuous user feedback and automated literature surveillance to preserve patient safety and guideline fidelity."

Cytokine release syndrome • Inflammation

Impact of antibiotic use in early fever after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (ASH 2025) - "All patients received PTCY 50 mg/kg on days +3 and +4, followed by tacrolimus and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis...Eleven patients received tocilizumab for CRS grade ≥2. Levofloxacin prophylaxis was used in 72.8% of cases. Most (85/103, 82.5%) received empirical BSA, mainly piperacillin/tazobactam (67%)... The median patient age was 53 years, and 60.3% were male. The most frequent diagnosis was AML (38.8%). Most patients had intermediate disease risk (65.3%) and a high age-adjusted HCT-CI (76%)."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Pneumonia • Transplantation • CRP

Aberrant lymphocytes are associated with increased inflammatory complications following CAR-T infusion (ASH 2025) - "CAR-T products included axi-cel (Yescarta) (n=10), brexu-cel (Tecartus) (n=2), liso-cel (Breyanzi) (n=1), tisa-cel (Kymriah) (n=1), or CD19-Car_Lenti (produced by the Officina Farmaceutica of Bambino Gesù Children's Hospital) (n=2)...Associations were not found between number of aberrant lymphocytes and development of neurotoxicity (eg, ICANS) nor with doses of Tocilizumab, Dexamethasone, or Anakinra or with WBC. While the number of patients is small, presence of increased aberrant lymphocytes, as pre-classified by the Scopio full-field digital morphology platform, appears to be associated with increased inflammatory complications following CAR-T infusion, including CRS of grade ≥2 and prolonged neutropenia requiring G-CSF support. Digital morphology combined with artificial intelligence may represent a novel platform for predicting clinical outcomes in CAR-T therapy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Rheumatology

CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: Real-world outcomes from a comprehensive cancer center (ASH 2025) - "Treatment options included ciltacabtagene autoleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel...Secondary outcomes included use of tocilizumab, corticosteroids, vasopressors, anakinra, intrathecal chemotherapy, dasatinib, and thiamine; length of stay; survival at 100 days and 1 year... 53 patients were included in the study. Most patients receiving axi-cel experienced grade 1 or 2 CRS, with only three patients experiencing grade ≥3 CRS. The incidence of CRS was lower here compared to ZUMA-1 and ZUMA-5."

CAR T-Cell Therapy • Clinical • Cytokine release syndrome • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Tocilizumab prophylaxis in patients receiving CAR-T cell immunotherapy for hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Four studies examining 91 patients with hematological malignancies (B-cell non-Hodgkin lymphomas: 76, ALL: 6, in 9 not specified) receiving tocilizumab prophylaxis (1 dose, 8 mg/kg) before CAR-T therapy (Axicabtagene ciloleucel: 38, Tisagenlecleucel: 2, other CD19-CAR-T cell products: 43, in 8 not specified) were included in the qualitative analysis. Based on these data, tocilizumab prophylaxis prior to infusion in patients who receive CAR-T cell immunotherapy can significantly decrease the risk of both any grade and grade >2 CRS. ICANS incidence was similar to ongoing published data and more than half of patients receiving tocilizumab prophylaxis achieved PFS. The need for larger, randomized controlled trials to confirm the observed effects and determine the impact of prophylactic tocilizumab on OS, TRM, adverse events, and infectious complications is warranted."

CAR T-Cell Therapy • Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • IL6

A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of CTO1681 (GP1681) in healthy adult participants (ASH 2025) - P1 | "The current standard-of-care treatment for CRS is tocilizumab and/or corticosteroids. Latent viruses (EBV, HSV, VZV, and CMV) were not detected in any participant, and there were no reports of skin lesions that might be indicative of viral reactivation. The PK, PD, and safety data presented in this clinical study report supports further clinical development of CTO1681."

Clinical • PK/PD data • Hypotension • Immunology • Infectious Disease • Influenza • Respiratory Diseases • Systemic Inflammatory Response Syndrome

Which inflammation matters? distinct risk signatures before CAR-T cell therapy and the role of inflamix (ASH 2025) - "Next, we evaluated potential differences in the use of tocilizumab, steroid therapy, and intensive care unit (ICU) hospitalization between the two groups...Overall, 65 patients (71%) received axicabtagene ciloleucel (axicel), and 27 patients (29%) received tisagenlecleucel (tisacel)...Its divergence from mEASIX and CAR-HEMATOTOX suggests that it reflects a distinct inflammatory profile. This underscores the importance of incorporating multiple biomarkers to enhance risk stratification."

CAR T-Cell Therapy • IO biomarker • Hematological Disorders • Hematological Malignancies • Inflammation • Lymphoma • Neutropenia

Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience (ASH 2025) - "Cytokine release syndrome (CRS) occurred in 62% (39% grade 2–4; 23% grade 3–4), with 93% receiving tocilizumab. We included 19 patients with a median follow-up of 16 months. The mean age was 70.4 years (SD=11.7) and 43% had high-risk cytogenetics (62% Double/Triple-hit) by mSMART criteria. The median number of prior therapy lines was 4 (47% had 2–3 lines; 32%, 4–5; 21%, ≥6)."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Multiple Myeloma • Rare Diseases

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis (ASH 2025) - "The Bispecific antibodies used were Teclistamab. Eltranatamab, Talquetamab, and Linvoseltamab... Tocilizumab is a viable option for preventing all grades of CRS and ICANS following CAR-T cell therapy and Bispecific antibodies. Randomized trials with larger patient populations are needed to further demonstrate its efficacy, safety, and the impact on treatment responses."

Cytokine release syndrome • Retrospective data • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Inflammation • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes (ASH 2025) - "87.5% (14/16) of these patients received tocilizumab. Grade 1 ICANS was highest severity observed in 19% (4/21) of patients, requiring treatment with steroids with or without anakinra... Outpatient administration of Ide-cel for RRMM is associated with a high incidence of early CRS and ICANS, often leading to unplanned hospitalizations. Lower baseline albumin and hemoglobin levels, along with elevated ferritin, may help identify patients at higher risk for complications. While these factors correlated with hospitalization risk, they did not predict survival in this small cohort."

Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment patterns reflected a triple-class refractory population, with high prior exposure to proteasome inhibitors (bortezomib 52%, carfilzomib 48%), IMiDs (lenalidomide 66%, pomalidomide 63%), and anti-CD38 antibodies (daratumumab 51%). Additionally, 35% had received CAR T-cell therapy, 39% underwent ASCT, 24% were treated with Teclistamab, and extramedullary disease and plasma cell leukemia were reported in 11% and 13% of patients, respectively...Grade ≥3 CRS and ICANS occurred in <10 patients each (2.4%), and 24% received tocilizumab for CRS... In this large, real-world cohort, Talquetamab demonstrated favorable short-term survival and a manageable safety profile, consistent with clinical trial data. The higher mortality observed may reflect the heavily pretreated, triple-class refractory population with advanced disease features and comorbidities often seen in real-world settings. Hematologic toxicities remained significant, while lower observed rates of..."

Real-world • Real-world evidence • Retrospective data • Dermatology • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience (ASH 2025) - "Twelve patients (46%) had received previous anti-BCMA therapy (8 belantamab, 2 both belantamab and teclistamab, 1 teclistamab and 1 idecel). Talquetamab was administered to 16 patients (61%), teclistamab to 8 (30%), elranatamab to 2 (8%)...Premedication for each step up dose included dexamethasone, acetaminophen and diphenhydramine...This data supported, in our center, the use of prophylactic tocilizumab in outpatient setting. Given these results, even if all CRS events were grade 1, remained fully manageable and ICANS were rare, the use of prophylactic tocilizumab could improve treatment safety, inpatient management, and ultimately support feasibility in the outpatient regimen."

Clinical • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Thrombocytopenia

Real-world data on anti-BCMA CAR-T in Brazil: A single-center retrospective case series (ASH 2025) - "Background : The treatment landscape for relapsed/refractory Multiple Myeloma (R/R MM) in Brazil is unique, with both BCMA CAR-T (ciltacabtagene autoleucel, cilta-cel) and bispecific antibodies (teclistamab, talquetamab, elranatamab) being available for patients who are triple class exposed, but without the necessity of a specific number of previous lines of therapy (LoTs). Ciltacel is also approved based on lenalidomide refractoriness and previous proteasome inhibitor exposure...Of the other 5 patients, 3 did not fulfill CARTITUDE-1 criteria due to cytopenia (2/3), previous BCMA therapy with teclistamab and belantamab mafodotin (1/3) and non-secretory disease (1/3)...Tocilizumab was commonly used (4/7)... Access to CAR-T therapy for multiple myeloma in Brazil is often marked by extensive delays, resulting in a prolonged and complex treatment journey. Most patients wouldn't have fulfilled inclusion/exclusion criteria for the clinical trials the led to ciltacel..."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Multiple Myeloma

9-year-old female presenting with l lower leg pain diagnosed with erdheim-chester disease (ECD) (ASH 2025) - "Cytokine panel was remarkable for elevation in IL6, and patient received bridging therapy with tocilizumab infusion. As no standard treatment guideline exist for pediatric patients with ECD, case reports have focused on use of and outcomes of therapies such as steroids, chemotherapy, interferon alfa and targeted biologics in attempt to better optimize treatment (Pegoraro et al., 2023). The aim of this report is to further highlight how ECD can present in pediatric populations and present treatment response to dabrafenib and targeted cytokine inhibition in a pediatric patient with BRAFV600E mutation and diffuse bony involvement."

Pain • Rare Diseases • IL6

Glofitamab-based combinatorial therapy demonstrates high efficacy in primary refractory and early relapsed DLBCL: Real-world evidence of durable responses and immune modulation in high-risk subgroups (ASH 2025) - "Tocilizumab was administered in 8.3% (1/12)...Notably, this activation persisted without exhaustion through 6 cycles, including in CAR-T–pretreated ( n =2) and bendamustine-exposed ( n =2) subgroups, suggesting sustained modulation of the tumor immune microenvironment... Glofitamab exhibits clinically significant activity in primary refractory and early relapsed DLBCL through potent T/NK-cell engagement, inducing durable responses across high-risk subtypes. Real-world data support combinability with Polatuzumab Vedotin, PD-1 immune checkpoint inhibitor, GemOx, BTKi, or radiotherapy, warranting proactive toxicity monitoring. These findings establish glofitamab as a transformative backbone therapy for resistant DLBCL, addressing critical unmet needs via its unique immune-redirecting mechanism."

Clinical • HEOR • IO biomarker • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Respiratory Diseases • CD20 • CD4 • CD5 • CD8 • TP53

Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network (ASH 2025) - "The analysis included data from 172 million patients across 151 healthcare organizations worldwide, predominantly academic centers in the U.S. Eligible patients had a confirmed diagnosis of R/R DLBCL, received ≥2 prior lines of systemic therapy including CAR T-cell therapy (axicabtagene ciloleucel or lisocabtagene maraleucel), were treated with epcoritamab, had an ECOG performance status of 0–2, and had ≥30 days of follow-up...Grade 3–4 CRS and ICANS occurred in ~4.1% of patients, and 25% received tocilizumab... In this real-world cohort, epcoritamab demonstrated favorable short-term survival in patients with R/R DLBCL following CAR T-cell therapy, mirroring results from the EPCORE NHL-1 trial. By limiting the cohort to patients with ECOG 0–2 and excluding prior transplant recipients, the study population closely resembled clinical trial eligibility. These findings support the broader applicability of epcoritamab in routine practice and highlight the importance of early..."

CAR T-Cell Therapy • Real-world • Real-world evidence • Retrospective data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Infectious Disease • Influenza • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pneumonia • Respiratory Diseases • Thrombocytopenia